Wonder where the Bird Flu Came From?

[Guest guest]

Please read both of these articles as it will blow your mind! Please note the dates. The first one is dated March 5, 2009; the second one is dated from 2007. The people behind this as at Baxter, Inc. should all be prosecuted and thrown in jail!

 

Were Tainted Vaccines a Conspiracy to Provoke a Pandemic?

(Dr. Mercola)

 

Czech newspapers are questioning whether the shocking discovery of vaccines contaminated with the deadly avian flu virus -- distributed to 18 countries by the American company Baxter -- were part of a conspiracy to provoke a pandemic.Because of laboratory protocols that are routine for vaccine makers, mixing a live virus biological weapon with vaccine material by accident is virtually impossible.Baxter flu vaccines contaminated with H5N1 (the human form of avian flu) were received by labs in the Czech Republic, Germany and Slovenia. Initially, Baxter refused to reveal how the vaccines were contaminated with H5N1, invoking “trade secrets.” After increased pressure, they then claimed that pure H5N1 batches were sent by accident.But in the Czech Republic, reporters are investigating whether the contamination was part of a deliberate attempt to start a pandemic. The fact that Baxter mixed the deadly H5N1 virus with a mix of H3N2 seasonal flu viruses may be the smoking gun. The H5N1 virus on its own has killed hundreds of people, but it is less airborne. However, when combined with seasonal flu viruses, which are more easily spread, the effect could be a potent, airborne, deadly biological weapon.

Sources:

PrisonPlanet.com March 5, 2009

 

 

Baxter International Inc. has announced that Baxter's European subsidiary in the United Kingdom has entered into an advanced supply agreement with the Department of Health that contains an option to purchase pandemic influenza vaccine in the event the World Health Organization (WHO) declares a pandemic.

Baxter will manufacture its pandemic vaccine in a serum-free, vero cell-based system, at one of the largest cell culture vaccine facilities in the world. The use of vero cell culture, rather than conventional egg-based technology, offers several advantages. Baxter's vero cell culture process can be initiated more rapidly due to its use of a "native" virus that does not need to be modified to allow growth in eggs, thus accelerating vaccine availability. Vaccines produced using this process can be released within approximately 12 weeks, significantly earlier than with traditional egg-based systems. In addition, all influenza strains with pandemic potential tested for growth in vero cells have produced replicable high yields, providing the company with the flexibility to quickly respond to emerging variant pandemic virus strains.

"We are proud to provide the necessary technology, manufacturing capability and other resources to assist the Department of Health in its efforts to protect the UK population from the threat of a flu pandemic," said Kim Bush, president of Baxter's vaccines business.

Baxter is conducting clinical testing of the adjuvant-free candidate H5N1 (avian) influenza vaccine. A Phase I/II study in Europe indicated that study subjects administered Baxter's H5N1 candidate vaccine developed excellent antibody responses at doses as low as 3.75microg and substantial levels of cross immunity against widely divergent H5N1 strains. In the study, the tolerability profile of Baxter's H5N1 candidate appeared to be similar to that of seasonal flu vaccines. Baxter recently completed enrollment in a 550 subject Phase III trial of the H5N1 candidate vaccine for mock-up licensure in Europe, with data from this clinical study expected to be available in late 2007. By this time, Baxter is planning to initiate an additional large Phase III clinical study intended to satisfy all European requirements for pre-pandemic licensure. Baxter is also working with the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, in partnership with Fisher BioServices Inc., and with the U.S. Department of Health and Human Services, in partnership with DVC LLC, a Computer Science Corporation Company, to further develop vero cell culture-based candidate pandemic and seasonal influenza vaccines in the United States.

Baxter's candidate vaccine's antigen composition and structure closely resembles the actual pathogen circulating in nature. The candidate vaccine induces an immune response that is similar to the body's defense against a natural virus, without the need to incorporate additional agents (adjuvants) to enhance immune response. It is believed that adjuvants may contribute to additional side effects in vaccines.

Supporting Pandemic Preparedness

In addition to pursuing a rapid clinical development program, Baxter is working closely with governments around the world on pandemic preparation. Baxter has already delivered several million doses of H5N1 pre-pandemic vaccine to various governments worldwide. In 2006, Baxter entered into a pandemic preparedness contract with the Austrian Ministry of Health to supply 16 million doses of pandemic influenza vaccine in the event a pandemic is declared.

http://www.baxter.com/

"I feel ashamed that so many of us cannot imagine a better way to do things than locking children up all day in cells instead of letting them grow up knowing their families, mingling with the world, assuming real obligations, striving to be independent and self-reliant and free." - John Taylor Gatto Quick access to Windows Live and your favorite MSN content with Internet Explorer 8.